WHO Raises Alert Over Critical Shortage of Weight-Loss Jabs
Less than a tenth of individuals who could benefit from obesity jabs like Wegovy are able to get them, states the global health agency as it publishes its inaugural advice on the therapies.
Considering more than one billion individuals worldwide currently obese, it is advocating for increased and just access to GLP-1 medication.
Based on forecasts, over two billion could be living with obesity by 2030 without intervention.
"Our new guidance acknowledges that obesity is a lifelong illness that can be managed with holistic and ongoing care," remarked its chief Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and logistical bottlenecks are significant barriers to broad availability to the jabs that can help people shift significant body mass, says the organization.
GLP-1 Therapy Scarcity
Even under the current best projected case, the manufacturing of such drugs would only suffice for about 100 million people – fewer than 10% of the global need, as stated by the WHO.
The advice encourages countries and companies to widen access, via approaches including licensing agreements.
The intellectual property rights on the active ingredient – the core component of Novo Nordisk's Wegovy – is scheduled to end in a number of nations in 2026.
How Obesity Jabs Operate
These medications mimick a natural hormone to slow digestion, suppress the appetite and enhance satiety so users eat less.
People usually start to lose weight after several weeks of commencing the once-weekly jabs.
Studies suggests users may see weight return after a year of stopping the medication, because their normal food cravings resume.
To be overweight or obese elevates your chance for experiencing health problems, such as diabetes, heart disease, stroke, and specific cancers.
Obesity concerns individuals in all nations and was responsible for over three and a half million fatalities worldwide in 2024, according to the WHO.
